PT - JOURNAL ARTICLE AU - Scaggiante, Jacopo AU - Pedicelli, Alessandro AU - Marsico, Salvatore AU - Casà, Calogero AU - Miccichè, Francesco AU - Garignano, Giuseppe AU - Alexandre, Andrea AU - Valente, Iacopo AU - D’argento, Francesco AU - Ferrante, Monica AU - Sala, Evis AU - Squillaci, Ettore TI - P176 Percutaneous microwave ablation of painful spinal metastasis: an updated systematic review of analgesia and safety AID - 10.1136/jnis-2024-ESMINT.211 DP - 2024 Sep 01 TA - Journal of NeuroInterventional Surgery PG - A122--A122 VI - 16 IP - Suppl 2 4099 - http://jnis.bmj.com/content/16/Suppl_2/A122.2.short 4100 - http://jnis.bmj.com/content/16/Suppl_2/A122.2.full SO - J NeuroIntervent Surg2024 Sep 01; 16 AB - Introduction Microwave ablation (MWA) is a promising minimally invasive technique for treating spinal metastases, creating larger ablation zones, reducing procedural times, and effectively ablating high-impedance tissues.Aim of Study To evaluate the efficacy and safety of MWA in managing pain associated with spinal metastases.Methods A systematic search and analysis were conducted following PRISMA guidelines. Studies were included if they met the following criteria:Randomized or non-randomized studies with at least 3 patients (prospective or retrospective)Adult patients with spinal metastasesMWA used alone or combined with other treatmentsReported pre- and post-MWA pain assessmentsPublished in EnglishData on demographics, tumor type, lesion location, pain scores, and complications were extracted.Results The search yielded 14 studies encompassing over 481 patients(M:F=1:1) with 836 treated lesions. All studies reported achieving partial pain response based on International Consensus Endpoint after Radiation Therapy criteria. Additionally, 85.7% of studies showed highly effective pain management (≥4-point reduction on a pain scale to the last follow-up). Lung(35.4%), breast(25%), and gastrointestinal(12.5%) cancers were the most common primary tumors. The thoracic spine was the most frequent site (47%), followed by lumbar (41.3%) and sacral (11.2%). No major complications were observed.Conclusion This systematic review suggests that MWA, often used in combination with vertebral augmentation, represents a safe and effective treatment for achieving short- to mid-term (24 hours to 6 months) pain control in patients with spinal metastases.Disclosure of Interest no.